Lipodystrophy is abnormal central fat accumulation or localized loss of fat tissue or mixed clinical presentations representing both. It is also known as the Lawrence-Seip syndrome, a rare group of syndromes, either acquired or congenital. People with lipodystrophy experience an uncontrolled loss of fat tissue, especially fat under the skin. This causes a drop in an important hormone called leptin. Without enough fat tissue or Leptin, the body's system for regulating energy use falls out of balance.

As per the Lipodystrophy United, the global prevalence of lipodystrophy has been estimated at less than 1 case in 100,000 people. According to an article published in the Journal of Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, in 2017 in Europe, the prevalence of lipodystrophy was 2.63 cases/million. The two most common acquired varieties of lipodystrophy include acquired generalized lipodystrophy and acquired partial lipodystrophy. Highly active antiretroviral therapy-induced lipodystrophy in HIV-infected patients and drug-induced localized lipodystrophy are other common sub-types. Lipodystrophy is a rare disease that affects fewer than 200,000 people in the U.S.. The global lipodystrophy treatment market is expected to expand at a robust pace during the forecast period. High return on investments for the development of orphan drugs, strong research and development initiatives for orphan drugs in developed countries, and increase in the number of rare diseases related to genetic mutations that are treated using orphan drugs are expected to drive the market in the coming years.

The global lipodystrophy treatment market can be segmented based on disease, drug class, end-user, and region. Based on disease, the lipodystrophy treatment market can be divided into acquired generalized lipodystrophy and acquired partial lipodystrophy. Till now, there is no cure for lipodystrophy, and the effects of treatment vary from person to person. There is only one FDA-approved treatment for generalized lipodystrophy (myalept), and there are no approved treatments for partial lipodystrophy. In terms of end-user, the global lipodystrophy treatment market ca be segmented into academic & research institutes, hospital, and others. Increase in R&D in the health care sector, which utilizes gene sequencing for the testing of orphan diseases, is expected to drive the lipodystrophy treatment market during the forecast period.

High rate of growth of the lipodystrophy treatment market can be attributed to the entry of novel, expensive therapies and high unmet needs. More high-priced therapies are expected during the forecast period. Kalydeco for cystic fibrosis and exon-skipping therapies for Duchenne muscular dystrophy are new therapies introduced in the market. Competitive activity is increasing as larger companies realize the rewards of investing in orphan therapeutics. High unmet needs and low competition in several regions are expected to attract more companies to the market in the near future.

Based on region, the lipodystrophy treatment market can be categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for a major share of the lipodystrophy treatment market. According to a report of Research Office, Legislative Council Secretariat, there are between 25-30 million people suffering from rare diseases in the U.S.. Strong focus on research and development and government aids, such as research grants, tax credits, and fee waivers, to promote R&D contribute to the growth of the market. As a result, over 4,171 drugs have been designated the orphan drug status in the U.S. as of June 2017. In addition, favorable reimbursement offered by the government and private payers for the treatment of rare diseases drives the market in the region.

Europe is a prominent region of the orphan drugs market. According to a Research Office Legislative Council Secretariat report, in 2015, over 30 million people were suffering from rare diseases in the European Union. Incentives offered to promote the manufacture of orphan drugs in the region, such as a10-year period of marketing exclusivity, research grants, and reduced fees for marketing authorization applications, aid in the expansion of the market. Over 1,805 drugs have been granted orphan drug status in the European Union, and over 128 drugs were granted marketing authority from 2000 to 2016.

Players operating in the global market are Aegerion Pharmaceuticals, Inc. Akcea Therapeutics Inc, Ambrx, Inc., Amunix Operating Inc., Bolder Biotechnology, Inc., Theratechnologies Inc., GlaxoSmithKline plc, Novelion Therapeutics Inc., and Sun Pharmaceutical Industries Limited.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Lipodystrophy Treatment Market

Pre Book